Cernostics is a life science company developing new molecular diagnostic tests to treat cancer.
Cernostics is a life science company developing new molecular diagnostic tests for the fight against cancer. Most current diagnostic approaches offer a limited view of cancer because they fail to evaluate the tumor as a system composed of multiple cell types, not merely tumor cells.Its patent-protected technology platform, TissueCypher, uniquely analyzes whole slide digital images with multiplexed fluorescence, providing greater information and accuracy than traditional subjective tissue diagnostics.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 13, 2021 | Series Unknown | $5.98M | — | — | — | Detail |
Mar 21, 2018 | Series A | $2.50M | 1 | Illumina Ventures | — | Detail |
Aug 31, 2016 | Series Unknown | $5M | 2 | UPMC | — | Detail |
Jun 8, 2015 | Series Unknown | $1.96M | 1 | Ben Franklin Technology Partners of Northeastern Pennsylvania | — | Detail |
Feb 20, 2014 | Series Unknown | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Illumina Ventures | Yes | Series A |
UPMC | Yes | Series Unknown |
Ben Franklin Technology Partners of Northeastern Pennsylvania | Yes | Series Unknown |
Novitas Capital | — | Series Unknown |
Geisinger | — | Series B |
Pittsburgh Life Sciences Greenhouse | — | Series B |
Geisinger Ventures | — | Series A |